Semaglutide tablety: what the UK's first oral weight-loss tablet actually does

The biggest misconception: Wegovy tablets are not a weaker version of the injection

Many people assume that because semaglutide tablety come in a tablet form, they must be a lighter or less effective option than the injection. That is not accurate. The Wegovy tablet was designed to reach a higher maintenance dose (25 mg) than the standard 2.4 mg weekly injection, and the two are intended as distinct treatment pathways rather than a hierarchy. The tablet includes an absorption enhancer called SNAC, which allows semaglutide to cross the gut lining into the bloodstream, something most large peptide molecules cannot do on their own.

In the OASIS 4 phase-3 trial, which followed 307 adults with obesity or overweight and at least one weight-related condition over 64 weeks, participants taking the tablet lost an average of around 13.6% of their body weight compared with roughly 2.4% on placebo, both alongside lifestyle changes. Among those who adhered fully to treatment throughout, average weight loss reached approximately 16.6%. If you see the higher figure quoted anywhere, it is important to understand it reflects full adherence in a clinical trial setting, not a guaranteed real-world outcome. More detail on the underlying semaglutide evidence is covered on our semaglutide overview page.

The most common side effects in the trial were gastrointestinal: roughly three quarters of tablet users reported nausea, diarrhoea or similar symptoms at some point, versus around two fifths on placebo. These were mostly mild to moderate and tended to settle as the body adjusted, particularly if the dose escalation schedule was followed carefully. They reflect the same GLP-1 mechanism seen across the semaglutide range, slowing gastric emptying and reducing appetite signals from the brain.

How semaglutide tablets are taken, the detail most people miss

The practical rules around taking Wegovy tablets are stricter than for most daily medications, and getting them wrong affects how well the tablet works. Semaglutide has very low oral bioavailability by default; the SNAC absorption mechanism depends on a precise set of conditions. The tablet is taken first thing in the morning, on a completely empty stomach, with no more than a small sip of plain water, up to about 120 ml. Nothing else passes by mouth for at least 30 minutes afterwards: no coffee, no tea, no food, no other tablets.

In practice that means building it into the very start of your morning before the kettle goes on. The wait is not optional. If the 30-minute window is missed or broken by food or drink, absorption is reduced and the dose is effectively wasted. The tablet is swallowed whole; it should not be crushed or chewed.

Storage is considerably simpler than for the injection. Wegovy tablets stay at room temperature with no need for a fridge, which removes one of the practical hurdles that some patients find off-putting about injectable treatment. For the full prescribing detail (including exactly what happens if you miss a dose) the semaglutide dosing guidance page is a useful reference, and the official Patient Information Leaflet for Wegovy tablets is the definitive source. You can also explore how the injectable form compares on our Wegovy injection page.

Who the tablet is licensed for, and the NHS picture right now

The MHRA licence covers adults with a BMI of 30 or above, and adults with a BMI between 27 and 29.9 who also have at least one weight-related condition such as high blood pressure, raised cholesterol, type 2 diabetes, or obstructive sleep apnoea. Treatment must sit alongside a reduced-calorie diet and increased physical activity. Wegovy tablets are not licensed for anyone under 18, and they are not recommended during pregnancy, while breastfeeding, or when trying to conceive.

The NHS does not currently fund Wegovy tablets. A NICE appraisal would be required before they could be commissioned, and that process takes time; the injection form went through NICE before becoming available through specialist NHS weight management services under NICE guidance TA875. For now, Wegovy tablets are available through a private prescription following clinical assessment. If you are already on the 2.4 mg weekly injection, the prescribing information indicates that patients established at that dose may move to the 25 mg tablet subject to clinical review, but that is a decision made with your prescriber, not a self-directed switch. Our Wegovy tabletter page covers more on where the tablet fits within the broader Wegovy range.

For context on cost, which is one of the most common questions we receive about the tablet, our Wegovy price page explains what goes into a legitimate private prescription price. There have also been supply questions for the injection in recent months; our Wegovy shortage page explains the current situation. Anyone interested in the broader range of licensed treatment options can explore them on the weight-loss treatments overview.

Semaglutide tablets versus the injection: not a direct swap

A question our prescribers hear regularly is whether someone can simply choose the tablet over the injection as a matter of preference. The honest answer is: sometimes yes, but the two are not clinically identical in every respect, and a prescriber assesses which pathway suits a patient's full picture. The dose schedules are different. The bioavailability is lower for the tablet (absorption via the gut is inherently less consistent than a subcutaneous injection), which is why the maintenance dose is so much higher at 25 mg. Head-to-head trial data comparing the two directly in weight management is still limited at the time of writing.

Both forms activate the GLP-1 receptor, slow gastric emptying, and reduce appetite. Both carry the same core contraindications and precautions. The practical differences (daily versus weekly dosing, morning fasting requirements versus injection-site rotation, no fridge needed versus pen storage) matter differently for different people. There is no universally superior option; suitability is individual.

If you would like to understand how our prescribers approach semaglutide (including the injectable form) the information on the 1 mg semaglutide dose and the 2 mg semaglutide page give useful context on the injection pathway. Our clinical team's approach is set out on the clinical team page. When you are ready to explore whether Wegovy tablets or another licensed treatment fits your situation, speaking to our prescribers through a free consultation is the right first step.